Eli Lilly 2015 Annual Report Download - page 119

Download and view the complete annual report

Please find page 119 of the 2015 Eli Lilly annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 186

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176
  • 177
  • 178
  • 179
  • 180
  • 181
  • 182
  • 183
  • 184
  • 185
  • 186

P3
Innovation Progress
We made significant advances with our pipeline in 2015, including:
• U.S. FDA approval of six new products, including Portrazza™, in combination with gecitabine and
cisplatin, Cyramza® for treatment of colorectal cancer, Glyxambi®, Basaglar®, and Synjardy®.
• A late-stage pipeline including 9 potential new medicines or diagnostic agents in either Phase III
development or submission stage.
• FDA Breakthrough Therapy Designations for abemaciclib for patients with refractory hormone-
receptor-positive advanced or metastatic breast cancer and for olaratumab for advanced or
metastatic soft-tissue sarcoma.
• Positive Phase III results for ixekizumab, an investigational medicine for patients with psoriatic
arthritis.
• Positive Phase III results for baricitinib, an investigational medicine for patients with moderately-to-
severely active rheumatoid arthritis.
• Positive results from a long-term clinical trial investigating cardiovascular outcomes for Jardiance®.
Returns to Shareholders
We generated strong total shareholder returns (share price appreciation plus dividends, reinvested quarterly)
for the one-, three-, and five-year periods through year-end 2015, including a 25% percent increase from
2014 to 2015. Our returns exceeded both the compensation peer group and the S&P 500 in all three periods:
Consistent with our ongoing commitment to returning excess cash to shareholders, we returned
approximately $2.9 billion in cash to shareholders in 2015 in the form of dividends and share repurchases. In
the past five years, we have returned $12.5 billion in cash to shareholders through dividends and share
repurchases.
four